Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdvanDrop Bev is a proprietary oral formulation technology developed by Healthcann that enhances the solubility and bioavailability of cannabinoids, particularly cannabidiol (CBD). The technology enables water-soluble formulations of CBD, resulting in significantly faster absorption and higher systemic exposure compared to traditional oil-based tinctures. This allows for rapid onset of action and more predictable drug delivery when administered orally. The mechanism involves improving the dissolution rate of cannabinoids, thereby bypassing the slow absorption typically seen with crystalline forms. The primary indication is for cannabinoid-based therapeutics targeting conditions where CBD’s anti-inflammatory, anti-oxidative, and neuroprotective effects are beneficial[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AdvanDrop Bev.